Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression

Recently, the immune checkpoint inhibitor (ICI) pembrolizumab was demonstrated to be superior to platinum doublet chemotherapy in the first-line setting in patients with tumor programmed death-ligand 1 (PD-L1) expression of at least 50%. However, because patients with epidermal growth factor recepto...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Transl Med
Autors principals: Uenami, Takeshi, Ishijima, Mikako, Kanazu, Masaki, Kurebe, Hiroyuki, Edahiro, Ryuya, Nishida, Kohei, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6281532/
https://ncbi.nlm.nih.gov/pubmed/30596074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2018.10.24
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars